Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE
  4. Index of Suspicion

MinuteCE®

Index of Suspicion

Introduction to Right Heart Catheterization

ReachMD Healthcare Image
Restart
Resume
Choose a format
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    The index of suspicion prepares you to identify factors leading to the pre-test probability. Learn about tests such as the ECHO and PFT, along with other tests to consider to raise the index of suspicion. The role of comorbidities in the right heart catheterization (RHC) process is also discussed, as well as the various definitions associated with RHC and the role of RHC in the diagnostic algorithm.

  • Target Audience

    This activity has been designed to meet the educational needs of Cardiologists and Pulmonologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Identify the factors and tests to be considered with the pre-test probability 
    • Define comorbidities in the RHC paradigm
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for 0.50 contact hours/0.05 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-056-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).  

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Host: 
    Vallerie V. McLaughlin, MD, FACC, FAHA
    Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine 
    Interim Chief Clinical Officer, University of Michigan Medical Group
    Director, Pulmonary Hypertension Program 
    University of Michigan 
    Ann Arbor, MI

    Dr. McLaughlin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Research: Aerovate, Altavant, Goassamer-Bio, Janssen, Merck, Sonovie
    Consulting Fees: Aerami, Aerovate, Altavant, Caremark, LLC, Corvista, Gossamer-Bio, Janssen, Merck, United Therapeutics
     
    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose. 
    • Tim Person has nothing to disclose. 
    • Prerna Poojary, PhD, has nothing to disclose. 
    • Susan Diaz has nothing to disclose. 
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC

  • Commercial Support

    This activity is supported by an independent educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medical Masterclass, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule26 Nov 2024